Handelsavisen
prelaunch
UP
UPXI.O NASDAQ Personal Products

Upexi, Inc

$0,81
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
56,2M USD
P/E
EV / Rev
5,0x
Div yield
Op margin
-96,5 %
ROE
-18,7 %
Net margin
-78,9 %
Debt / equity
1,21
Beta
52w range
Volume
29,9k
Day range
$1,16–$1,24
Prev close
$1,21
Open
$1,22
Next earnings
2026-08-09
Ex-dividend
TR 1Y
About

Upexi, Inc is a personal products company that offers a range of consumer goods within the personal care segment, generating revenue primarily through the sale of these products to consumers.

Business. Upexi, Inc. (UPXI.O) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification99 %
SectorConsumer Staples
Industry groupPersonal Products
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target5,00

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
5,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
-18,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning UPXI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to UPXI.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Upexi, Inc. (UPXI.O) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification99 %
    SectorConsumer Staples
    Industry groupPersonal Products
    AI synthesis
    GENERATED

    Upexi, Inc has a market capitalization of $106.04 million and a price-to-book ratio of 4.81, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 0.7, suggesting that it has less current assets than current liabilities, which could pose a liquidity risk. The debt-to-equity ratio of 1.21 indicates that the company is financed by a combination of debt and equity, with a slight tilt towards debt.

    In terms of profitability, Upexi, Inc reported a net loss of $4.12 million and an operating loss of $5.04 million, which is significantly below the industry median for profitability metrics. The return on equity of -18.67% and return on assets of -7.29% further underscore the company's unprofitable operations. These figures suggest that the company is not generating returns that meet the expectations of its shareholders or asset base.

    The company's revenue is concentrated in a single business segment, as there are no disclosed segments, and there is no information on geographic exposure. This lack of diversification could expose the company to higher risk if the personal products market experiences a downturn.

    The growth trajectory of Upexi, Inc is not clearly defined, as there is no outlook data provided for the current or next fiscal year. The company's operating cash flow is negative at -$2.82 million, and its free cash flow is also negative at -$1.96 million, indicating that the company is not generating sufficient cash from operations to fund its activities.

    The risk assessment for Upexi, Inc highlights a medium liquidity risk and a low dilution risk. The company's capital structure includes a significant amount of long-term debt, which could lead to financial distress if the company is unable to meet its debt obligations. The risk of dilution is low, as there is no indication of a large number of shares outstanding or a potential for a significant increase in shares.

    Recent events related to Upexi, Inc include analyst estimates that suggest a wide range of price targets, from $2.00 to $8.00, with a mean and median price target of $5.00. The mean recommendation from analysts is 2.00, which is a "Buy" rating, indicating that analysts are generally optimistic about the company's future performance.

    Key takeaways
    • Upexi, Inc is currently unprofitable, with a net loss and operating loss, and a negative return on equity and assets.
    • The company's liquidity position is weak, as indicated by a current ratio of 0.7 and a negative operating cash flow.
    • The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.21.
    • Analysts have a generally positive outlook on the company, with a mean recommendation of "Buy" and a mean price target of $5.00.
    • margin_outlook_rationale: The company's margin outlook is negative due to its unprofitable operations and negative return on equity and assets.
    • rd_outlook_rationale: There is no information provided on the company's research and development activities or outlook.
    • capex_outlook_rationale: The company's capital expenditure is negative, indicating a reduction in investment in long-term assets.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Analysts project 488% upside to a $5.00 mean price target, signaling strong potential for significant share price appreciation.

    The company maintains a current ratio of 1.74, indicating sufficient short-term liquidity to cover immediate operational obligations.

    Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

    BEAR CASE · 2

    Debt-to-equity ratio of 1.21 is in the bottom quartile, signaling excessive leverage compared to the 0.13 peer median.

    Interest coverage of -120.4 indicates the company cannot cover interest expenses with operating income, raising significant solvency concerns.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-10
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $8.1M, +101,0% YoY; Operating income −16 240,4% YoY.

    Revenue$8.1M+101,0 % YoY
    Operating income-$175.4M−16 240,4 % YoY
    Net income-$178.9M−13 649,6 % YoY
    Free cash flow-$215.8M−20 225,2 % YoY
    EPS
    Operating cash flow-$12.5M−271,0 % YoY
    Financials
    Income statement
    Revenue$8.1M
    Gross profit$6.7M
    Operating income-$175.4M
    Net income-$178.9M
    Margins
    Gross margin83.3%
    Operating margin-2177.9%
    Net margin-2222.1%
    FCF margin-2679.6%
    Balance sheet
    Total assets$271.1M
    Total liabilities$222.4M
    Total equity$48.7M
    Cash & equivalents
    Long-term debt$212.8M
    Cash flow
    Operating cash flow-$12.5M
    CapEx-$37.0M
    Free cash flow-$215.8M
    SBC
    P&L flow · revenue → net income
    Revenue $8.1MOperating costs $183.4MTax $3.6MNet income $178.9M
    Highlights
    • Revenue $8.1M, +101,0% YoY
    • Operating income −16 240,4% YoY
    • Net income −13 649,6% YoY
    • Free cash flow −20 225,2% YoY
    • Net margin -2222.1%

    Valuation TTM

    Market price
    $0,81
    Market cap
    $106.0M
    Enterprise value
    $132.7M
    P/E
    Non-GAAP P/E
    EV / Revenue
    5.0x
    EV / Op income
    EV / OCF
    P / B
    4.8x
    P / Tangible book
    4.8x
    Tangible book
    $22.1M
    Net cash
    -$26.7M
    Current ratio
    0.7
    Debt / equity
    1.2
    ROA
    -7.3%
    ROE
    -18.7%
    Cash conversion
    68.0%
    CapEx / revenue
    -12.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYConsumer Non-CyclicalsIndustryPersonal Products215,0B node revenuePG 39,2%UL 26,8%CL 9,5%KMB 7,7%KVUE 7,0%EL 6,7%ELF 0,8%MATW 0,7%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered setUPXI 0,0% · rank #16 of 19

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs UPXI · multiples and returns
    PG
    PG
    THE PROCTER & GAMBLE COMPANY
    $144,97
    351,7B USD
    P/E
    22,1x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    29,2 %
    +47,9 vs self
    UL
    UL
    UNILEVER PLC
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    CL
    CL
    Colgate-palmolive Co
    $89,71
    72,1B USD
    P/E
    34,4x
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    903,4 %
    +922,1 vs self
    KM
    KMB
    KIMBERLY-CLARK INC.
    $108,01
    35,9B USD
    P/E
    60,0x
    vs self
    Div yield
    5,2 %
    vs self
    ROE
    47,9 %
    +66,6 vs self
    KV
    KVUE
    KENVUE INC.
    $18,04
    34,6B USD
    P/E
    22,7x
    vs self
    Div yield
    4,3 %
    vs self
    ROE
    15,1 %
    +33,7 vs self
    EL
    EL
    Estee Lauder Companies
    $84,68
    30,9B USD
    P/E
    101,7x
    vs self
    Div yield
    2,1 %
    vs self
    ROE
    7,5 %
    +26,1 vs self
    EL
    ELF
    Elf Beauty Inc
    $83,56
    5,0B USD
    P/E
    174,5x
    vs self
    Div yield
    vs self
    ROE
    2,3 %
    +21,0 vs self
    MA
    MATW
    Matthews Intl Corp
    $28,07
    873,7M USD
    P/E
    vs self
    Div yield
    3,6 %
    vs self
    ROE
    -5,1 %
    +13,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,94
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-1,94
    Revenueno estimateno estimate29,8M USD
    Operating incomeno estimateno estimate-127,3M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$5,00 · Median $5,00
    Low $2,00High $8,00
    Operating income · consensus-127,3M USD
    EPS surprise
    +10,8 %
    reported vs consensus · beat
    Revenue surprise
    −46,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$2,00
    Mean$5,00
    Median$5,00
    High$8,00
    Spot$0,81
    +521.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-96,5 %Bottom quartile
    Net Margin-78,8 %Bottom quartile
    ROE-18,7 %Bottom quartile
    Capex / Rev-12,7 %Bottom quartile
    D/E1,21Bottom quartile
    Cash Conv0,68Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Upexi, Inc Market data — financials · 2026-05-29
    • Upexi, Inc Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Allan MarshallChairman of the Board, Chief Executive Officer

    Insider activity

    Net buying6 buys · 0 sellsnet $1,1M3 insiders · last 365d
    • MARSHALL ALLANDirector, Chief Executive Officer · Common StockBought 50 000 @ $1,80$90K · 2025-12-23
    • MARSHALL ALLANDirector, Chief Executive Officer · Common StockBought 50 000 @ $2,07$104K · 2025-12-16
    • MARSHALL ALLANDirector, Chief Executive Officer · Common StockBought 100 000 @ $2,07$207K · 2025-12-15
    • Salkind GeneDirector · Common StockBought 50 000 @ $2,55$128K · 2025-11-20
    • Salkind GeneDirector · Common StockBought 100 000 @ $2,81$281K · 2025-11-17
    • Salkind GeneDirector · Common StockBought 100 000 @ $2,65$265K · 2025-11-17
    • MARSHALL ALLANDirector, Chief Executive Officer · Common StockOther 1 600 000 · 2025-10-01
    • Norstrud Andrew JamesDirector, Chief Financial Officer · Common StockOther 240 000 · 2025-10-01

    Short positioning

    16.8Mshares short+0.4% vs prior
    9.69days to cover
    46.0%short of daily vol
    478fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    UPXI.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Current ratio (FY 2025-12-31): 2.20xDerived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 1,446.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,194.7%Derived (calculated)
    • Current liabilities (annual): USD 77.85MSEC XBRL filing
    • Shares outstanding (annual): 63.21MSEC XBRL filing
    • Total assets (annual): USD 271.14MSEC XBRL filing
    • Shareholders' equity (annual): USD 48.72MSEC XBRL filing
    • Current assets (annual): USD 171.25MSEC XBRL filing
    • Net margin (FY 2025-06-30): -86.5%Derived (calculated)
    • Revenue (YoY) (2025-06-30 vs 2024-06-30): -39.2%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): 44.4%Derived (calculated)
    • Gross margin (FY 2025-06-30): 68.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -8,208.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 92.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 92.5%Derived (calculated)
    • Capex (YoY) (2025-06-30 vs 2024-06-30): -58.4%Derived (calculated)
    • Gross profit (YoY) (2025-06-30 vs 2024-06-30): -15.3%Derived (calculated)
    • Net income (YoY) (2025-06-30 vs 2024-06-30): 42.2%Derived (calculated)
    • Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): -62.5%Derived (calculated)
    • Operating cash flow (annual): USD -8.42MSEC XBRL filing
    • Cost of revenue (annual): USD 4.94MSEC XBRL filing
    • Interest expense (annual): USD 103.81KSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
    • Pre-tax income (annual): USD -13.68MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-16FILINGFORM 8-K →
    2026-05-13FILINGFORM 8-K →
    2026-05-12FILINGFORM 10-Q →
    2026-05-07FILINGFORM 8-K →
    2026-05-05FILINGDEF 14A filing →
    2026-03-31FILINGFORM-8-K →
    2026-03-12FILINGFORM 8-K →
    2026-03-05FILINGFORM 8-K →
    2026-02-10 16:47 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 8.1M · Net USD -178.9M
    2026-02-10FILINGFORM 8-K →
    2026-02-10FILINGFORM 10-Q →
    2026-02-09FILINGFORM 8-K →
    2026-02-09FILING424B5 filing →
    2025-12-23 00:00 UTCINSIDER3 insider transactions — 2025-12 · net buy $400k
    2025-12-23INSIDERMARSHALL ALLAN bought 50.0k sh — Director, Chief Executive Officer ~$90k
    2025-12-16INSIDERMARSHALL ALLAN bought 50.0k sh — Director, Chief Executive Officer ~$104k
    2025-12-15INSIDERMARSHALL ALLAN bought 100.0k sh — Director, Chief Executive Officer ~$207k
    2025-11-20 00:00 UTCINSIDER3 insider transactions — 2025-11 · net buy $674k
    2025-11-20INSIDERSalkind Gene bought 50.0k sh — Director ~$128k
    2025-11-17INSIDERSalkind Gene bought 100.0k sh — Director ~$281k
    2025-11-11 17:25 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 9.2M · Net USD 66.7M
    2025-10-01 00:00 UTCINSIDER2 insider transactions — 2025-10
    2025-10-01INSIDERMARSHALL ALLAN transacted 1.60M sh — Director, Chief Executive Officer
    2025-10-01INSIDERNorstrud Andrew James transacted 240.0k sh — Director, Chief Financial Officer
    2025-09-24 17:01 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 4.3M · Net USD -6.9M
    2025-09-24 17:01 UTCEARNINGSAnnual results — FY 2025 Revenue USD 15.8M · Net USD -13.7M
    2025-07-22 00:00 UTCINSIDER13 insider transactions — 2025-07 · net buy $998k
    2025-04-17 00:00 UTCINSIDER7 insider transactions — 2025-04 · net buy $2.2M 2 derivative
    2025-03-12 00:00 UTCINSIDER1 insider transaction — 2025-03 1 derivative
    2025-01-17 00:00 UTCINSIDER3 insider transactions — 2025-01 3 derivative
    2024-12-16 17:27 UTCEARNINGSAnnual results — FY 2024 Revenue USD 26.0M · Net USD -23.7M
    2024-07-09 06:10 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 5.2M · Net USD -4.1M
    2024-03-12 00:00 UTCINSIDER3 insider transactions — 2024-03 · net buy $117k
    2023-10-03 06:07 UTCEARNINGSAnnual results — FY 2023 Revenue USD 36.4M · Net USD -16.9M
    2022-09-28 17:10 UTCEARNINGSAnnual results — FY 2022 Revenue USD 23.1M · Net USD -2.1M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage